HomeBlog of Signaling Pathways

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Blog of Signaling Pathways

Potential role of Acanthamoeba Rab7

123 views | Dec 26 2023

The study elucidates the pivotal role of AcRab7 in Acanthamoeba castellanii's phagocytosis, endosomal delivery, and cellular physiology, demonstrating its influence on energy production, cell proliferation, and potential implications for understanding related parasitic diseases. [Read the Full Post]

CD97 negatively regulates the innate immune response against RNA viruses by promoting RNF125-mediated RIG-I degradation

50 views | Dec 26 2023

The study reveals that the G protein-coupled receptor CD97 acts as a negative regulator of the antiviral immune response by promoting RIG-I degradation, suppressing IFN-I signaling, and offers potential for targeted antiviral therapies through inhibition of CD97. [Read the Full Post]

Myo/Nog Cells: The Jekylls and Hydes of the Lens

67 views | Dec 26 2023

This comprehensive study unveils the versatile behavior of Myo/Nog cells from embryonic development to adulthood, elucidating their crucial roles in eye formation, lens structure, and potential therapeutic avenues for preventing fibrotic diseases in ocular tissues. [Read the Full Post]

Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity

72 views | Dec 26 2023

ASP5878 (27) exhibits promising potential as a therapeutic candidate for treating bladder cancer by targeting FGFR3, boasting improved metabolic stability, minimal hERG channel inhibition, potent FGFR3 inhibition in vitro and in vivo, and favorable safety and pharmacokinetic profiles in preclinical models. [Read the Full Post]

Circ_0020014 mediates CTSB expression and participates in IL-1β-prompted chondrocyte injury via interacting with miR-24-3p

27 views | Dec 26 2023

This study elucidates the involvement of circ_0020014 in osteoarthritis by revealing its role as a regulator in IL-1β-induced chondrocyte injury through the circ_0020014/miR-24-3p/CTSB axis. [Read the Full Post]

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

74 views | Dec 25 2023

The evolution from a novel SETD2 inhibitor tool compound to the potent and orally bioavailable EZM0414 marks a significant achievement in drug development, promising potential clinical implications for conditions like multiple myeloma featuring a t(4,14) translocation. [Read the Full Post]

Heteroplasmic pathogenic m.12315G>A variant in MT-TL2 presenting with MELAS syndrome and depletion of nitric oxide donors

78 views | Dec 25 2023

This report highlights a 5-year-old child's neurological regression and stroke-like episodes associated with the MT-TL2 m.12315G>A mitochondrial variant, emphasizing the significance of detailed biochemical analyses and tailored treatments to expand the understanding and management of this rare condition. [Read the Full Post]

Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway

70 views | Dec 25 2023

Puerarin administration in spontaneously hypertensive rats demonstrated significant improvements in cardiac function and myocardial structure, potentially mediated by its inhibition of the TRPC6-CaN-NFATc3 pathway, suggesting promise for Puerarin as a therapeutic intervention in hypertensive myocardial remodeling. [Read the Full Post]

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

68 views | Dec 25 2023

"Through nanoparticle-based modulation of the tumor microenvironment, this review underscores a promising avenue to overcome immune resistance to PD-1/PD-L1 blockade in lung cancer, potentially revolutionizing the landscape of immunotherapy for these patients." [Read the Full Post]

Development and Validation of a Novel UHPLC-MS/MS Method for the Quantification of Plinabulin in Plasma and Its Application in a Pharmacokinetic Study with Leukopenic Rats

101 views | Dec 25 2023

This study on plinabulin's pharmacokinetics in rats suggests no significant differences between leukopenia and control groups, indicating its potential as a candidate for treating chemotherapy-induced leukopenia pending further human clinical trials. [Read the Full Post]

Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs

119 views | Dec 24 2023

Researchers systematically optimized coumarin analogs linked with the CDK9 inhibitor SNS-032, potentially enabling simultaneous binding to CDK9 and LC3B, initiating selective autophagic degradation and demonstrating potential for treating diseases associated with intracellular pathogenic proteins. [Read the Full Post]

CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer

52 views | Dec 24 2023

The study's use of CPI-203, a BRD4 inhibitor, in conjunction with PD-1 antibodies shows promising potential to overcome PD-L1-mediated resistance to immunotherapy in hepatocellular carcinoma. [Read the Full Post]

Synergistic Antibiofilm Action of Cinnamomum verum and Brazilian Green Propolis Hydroethanolic Extracts against Multidrug-Resistant Strains of Acinetobacter baumannii and Pseudomonas aeruginosa and Their Biocompatibility on Human Keratinocytes

110 views | Dec 24 2023

A study evaluating Cinnamomum verum and Brazilian green propolis extracts revealed their potent antibacterial and antibiofilm properties against multidrug-resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa, showcasing biocompatibility with human cells and suggesting a promising alternative approach to combat these pathogens. [Read the Full Post]

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer

43 views | Dec 24 2023

The development of SBP-7455, a dual ULK1/2 inhibitor showing potent activity against TNBC cells and synergistic effects with olaparib, suggests a promising strategy for treating triple-negative breast cancer by targeting autophagy and PARP pathways simultaneously. [Read the Full Post]

E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways

85 views | Dec 24 2023

E7050 demonstrates potent anti-tumor and anti-angiogenic effects by inhibiting VEGFR2 phosphorylation and downstream signaling pathways in endothelial cells, reducing neovessel formation in vitro and in vivo, and attenuating tumor growth and angiogenesis in a xenograft model, suggesting its promising potential as a therapeutic agent for cancer and angiogenesis-related disorders. [Read the Full Post]

NHWD-870 protects the kidney from ischemia/reperfusion injury by upregulating the PI3K/AKT signaling pathway (experimental study)

88 views | Dec 23 2023

NHWD-870 exhibits substantial nephroprotective effects by attenuating renal damage through its anti-apoptotic, anti-inflammatory, and antioxidant properties, indicating potential therapeutic promise in managing renal ischemia-reperfusion injury. [Read the Full Post]

Hepatocyte growth factor attenuates high glucose-disturbed mitochondrial dynamics in podocytes by decreasing ARF6-dependent DRP1 translocation

55 views | Dec 23 2023

This study illuminates the pivotal role of HGF in preserving mitochondrial homeostasis in diabetic podocytes via ARF6 activation, offering a novel pathway for mitigating renal damage in diabetic nephropathy. [Read the Full Post]

AZD5438 a GSK-3a/b and CDK inhibitor is antiapoptotic modulates mitochondrial activity and protects human neurons from mitochondrial toxins

0 views | Dec 23 2023

AZD5438, inhibiting CDKs and GSK-3a/b, emerges as a promising compound, showcasing potent neuroprotective effects by preventing mitochondrial dysfunction and neuronal damage induced by rotenone in human neurons, suggesting its potential therapeutic significance. [Read the Full Post]

Exercise attenuates neuronal degeneration in Parkinson's disease rat model by regulating the level of adenosine 2A receptor

275 views | Dec 23 2023

Exercise appears to mitigate Parkinson's disease symptoms in rats by reducing neurodegeneration through a-synuclein aggregation reduction and adenosine 2A receptor modulation, although the co-administration of an adenosine A2A receptor agonist reverses these beneficial effects. [Read the Full Post]

Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system

46 views | Dec 23 2023

Understanding the distinct adverse event profiles among MAO-B inhibitors like selegiline, rasagiline, and safinamide illuminates nuanced differences in their safety profiles, aiding clinicians in personalized Parkinson's disease management. [Read the Full Post]